Vertex Pharmaceuticals Incorporated with ticker code (VRTX) now have 29 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $602.00 and $325.00 with the average target price sitting at $515.77. Now with the previous closing price of $502.45 this indicates there is a potential upside of 2.7%. There is a 50 day moving average of $475.40 and the 200 day MA is $452.28. The market capitalization for the company is 133.08B. Currently the stock stands at: $516.74 USD
The potential market cap would be $136,603,371,192 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $41.19 and a 12.05% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
